OPN5-mediated reversal of T-cell exhaustion in CLL supports the use of BET inhibitors as important immunomodulatory agents, especially in combination with immune-based therapies such as checkpoint blockade or CAR-T therapy. Here, OPN5 is linked to B-cell chronic lymphocytic leukemia.